Enjoy complimentary customisation on priority with our Enterprise License!
Japan Regenerative medicine market size is estimated to grow by USD 2.33 billion at a CAGR of 15.89% between 2022 and 2027. The market in Japan is experiencing significant growth, driven by several key factors. Firstly, the increasing adoption of stem cell therapy is fueling market expansion. Stem cells possess the unique ability to develop into various cell types, making them an attractive solution for treating a wide range of diseases and injuries. Secondly, favorable government regulations are providing a conducive environment for the advancement of regenerative medicine in Japan. The Japanese Ministry of Health, Labor and Welfare has approved the use of several stem cell therapies, and the country's regulatory framework is considered one of the most advanced in the world. Lastly, Japan's aging population is another significant factor contributing to the growth of the regenerative medicine market. With an aging population comes an increased prevalence of age-related diseases and conditions, creating a significant demand for innovative medical solutions. The Japanese government is investing heavily in research and development to address this challenge, further boosting the market's growth prospects.
Stem cell therapy is a rapidly developing technology that can be applied to regenerative medicine. The use of stem cell technology in the treatment of diseases has increased its adoption rate. Furthermore, technological advances in stem cell-based therapies are changing the way researchers view regenerative medicine and are an important driver of these medical developments. Nanotechnology is also becoming increasingly important as a crucial tool in stem cell technology and regenerative medicine. Consequently, the growing adoption of stem cell technology will drive market size growth during the forecast period.
To learn more about this report, Request Free Sample
In company offerings, we provide an in-depth analysis of 20 top company profiles, along with other valuable insights comprising of:
• Company Overviews
• Key News and Updates
• Products and Services
• Market-leading Offerings
• Focused Segments
The following are the leading companies in the market. These companies are adopting various strategies, including strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to strengthen their market presence. Collectively, they hold the largest market share and set industry trends.
Terumo Corp.: The company offers regenerative medicine such as Finia fill and finish system, Quantum cell expansion system and spectra Optia apheresis system.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments
Based upon ,Application the market share growth by the oncology segment will be significant during the forecast period. Regenerative therapy is used to increase the ability of a patient's immune system to fight cancer. Oncology regenerative medicine treats blood-related diseases such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and leukemia. For example, the monoclonal antibody rituximab (Rituxan) is used to treat lymphoma and leukemia, and lenalidomide (Revlimid) can be used for multiple myeloma.
Get a glance at the market contribution of various segments View a PDF Sample
The oncology segment was valued at USD 417.64 million in 2017. This segment is driven by factors such as the rising incidence of cancer in Japan. Therefore, there is a growing need for effective oncology regenerative medicine. Additionally, the focus on precision medicine and oncology research is further increasing the demand for regenerative medicine. Therefore, such factors are expected to drive the growth of regenerative medicine in the oncology applications segment, which in turn is expected to propel the growth of the market during the forecast period.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends, and challenges. The Regenerative Medicine Market in Japan is rapidly advancing, driven by personalized medicine, gene therapies, and stem cell technologies. Strategic partnerships and collaborations are expanding the therapeutic area scope, particularly for rare genetic disorders like beta thalassemia. The Japanese healthcare framework supports significant investment in innovation, focusing on gene or cell-based therapies and tissue engineering products. However, ethical issues surrounding embryonic stem cells and regulatory pathways pose challenges. The aging population and increasing healthcare expenditure necessitate emerging technologies to address cardiovascular and other conditions in geriatric patients. With regulatory approvals and government support, Japan's market for personalized medications, cell-based immunotherapy, and tissue and organ transplantation continues to grow, fostering advancements in pharmaceuticals and biotechnology.
Increasing number of clinical trials is the primary trend shaping the growth of the market. The increase in the number of clinical trials is mainly due to increased efforts and support from various international and national public and private associations. Many regenerative medicine products are in various stages of clinical trials, from discovery or preclinical to mid- and late-stage.
Furthermore, the significant increase in the number of clinical trials suggests that healthcare providers are increasingly focusing on regenerative medicine research and development. Increasing the number of products successfully completing clinical trials and receiving product approval will drive Japan - regenerative medicine market growth. There are few products in late-stage (Phase III) clinical trials that are anticipated to propel growth in Japan's regenerative medicine market
The scarcity of tissue donors is a challenge that affects the growth of the market. Market players that simulate regenerative products depend heavily on the availability of tissue from human donors. Several potential donor families may be reluctant to donate tissue to commercial tissue processors. Additionally, many suppliers are facing human tissue supply shortages due to limited control over availability, quality, and delivery times.
Therefore, any interruption in the supply of human tissue components will negatively impact the supplier's ability to produce regenerative products until a new source is found. Therefore, the lack of tissue donors is restricting the growth of the Japanese regenerative medicine market.
Buy Now Full Report and Discover More
You may also be interested in:
Regenerative Medicine Market - Global Regenerative Medicine Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, Japan, China - Size and Forecast
Stem Cell Therapy Market - Stem Cell Therapy Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast
Cell Therapy Market - Cell Therapy Market - North America, Europe, EMEA, APAC : US, Canada, China, Germany, UK - Forecast
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
The Regenerative Medicine Market in Japan is witnessing significant advancements driven by stem cell research and 3D bioprinting. With a focus on chronic diseases like diabetes and cardiovascular disorders, Japan's pharma industry is leveraging bioengineering techniques and nanomaterials for innovative tissue engineering products. The market is bolstered by reimbursement policies and per capita income, despite ethical concerns surrounding human embryo use and legal and ethical concernsconcerns. Key applications include autologous cell therapy for cancer care, high performing biomaterials, ophthalmology, and neurology. Companies like Aspect Biosystems and Baxter are leading in cell therapy and artificial organ creation. However, the lack of awareness and regulatory frameworks pose challenges. Overall, Japan's regenerative medicine industry is set for robust market growth and forecasting.
Moreover, in treating conditions like Hemophilia B, Cerebral adrenoleukodystrophy, Refractory multiple myeloma, and Non-muscle bladder cancer. Leveraging 3D Printing and imaging technologies, the tissue engineering product market is focusing on orthopedic tissues and bones. An ecosystem analysis highlights the growth in the cell therapy segment, including both autologous therapy and allogenic therapy for musculoskeletal disorders and cardiovascular diseases. Key developments in stem cell banking, drug discovery, and cell immunotherapies are addressing the burden of chronic diseases. Innovations in nanografts, nanotubes, and nanofibrous scaffolds enhance wound care and orthopedic ailments. The market also benefits from advancements in drug delivery systems and wound management.
Market Scope |
|
Report Coverage |
Details |
Page number |
127 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 15.89% |
Market growth 2023-2027 |
USD 2.33 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
14.75 |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Astellas Pharma Inc., Becton Dickinson and Co., CellSeed Inc., Cellusion Inc., Cyfuse Biomedical K.K., F. Hoffmann La Roche Ltd., FUJIFILM Corp., HEALIOS K.K., iHeart Japan Corp., Japan Tissue Engineering Co. Ltd., JCR Pharmaceticals Co. Ltd., MEDINET Co. Ltd., Metcela Inc., Nikon Corp., ROHTO Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Takara Bio Inc., Takeda Pharmaceutical Co. Ltd., Terumo Corp., and Yokogawa Electric Corp. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the market forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Technology
8 Customer Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.